Healthcare - Medical - Diagnostics & Research - NYSE - US
$ 187.74
-4.65 %
$ 9.6 B
Market Cap
23.44
P/E
INCOME STATEMENT
4.13 B
REVENUE
617 M
OPERATING INCOME
480 M
NET INCOME
EFFICIENCY
Earnings Waterfall
Charles River Laboratories International, Inc.
| Revenue | 4.13 B |
| Cost Of Revenue | 2.63 B |
| Gross Profit | 1.5 B |
| Operating Expenses | 885 M |
| Operating Income | 617 M |
| Other Expenses | 137 M |
| Net Income | 480 M |
Income Statement
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | Dec-2014 | Dec-2013 | Dec-2012 | Dec-2011 | Dec-2010 | Dec-2009 | Dec-2008 | Dec-2007 | Dec-2006 | Dec-2005 | Dec-2004 | Dec-2003 | Dec-2002 | Dec-2001 | Dec-2000 | Dec-1999 | Dec-1998 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||||||||||||||||
| Revenue | 4 129.4 | 3 976.1 | 3 540.2 | 2 923.9 | 2 621.2 | 2 266.1 | 1 857.6 | 1 681.4 | 1 363.3 | 1 297.7 | 1 165.5 | 1 129.5 | 1 142.6 | 1 133.4 | 1 202.6 | 1 343.5 | 1 230.6 | 1 058.4 | 1 122.2 | 766.9 | 613.7 | 554.6 | 465.6 | 306.6 | 219.3 | 193.3 |
| GROSS PROFIT | ||||||||||||||||||||||||||
| Cost Of Revenue | 2 626.9 | 2 513.4 | 2 205.5 | 1 850.4 | 1 662.9 | 1 426.0 | 1 155.3 | 1 034.8 | 832.2 | 825.0 | 770.6 | 737.4 | 740.4 | 748.7 | 773.2 | 832.8 | 752.4 | 651.8 | 693.5 | 468.4 | 380.1 | 345.6 | 298.4 | 171.4 | 120.9 | 122.5 |
| Gross Profit | 1 502.6 | 1 462.7 | 1 334.6 | 1 073.5 | 958.3 | 840.1 | 702.3 | 646.7 | 531.1 | 472.7 | 394.9 | 392.1 | 402.2 | 384.8 | 429.4 | 510.7 | 478.2 | 406.6 | 428.7 | 298.6 | 233.7 | 209.0 | 167.3 | 135.1 | 98.4 | 70.8 |
| OPERATING INCOME | ||||||||||||||||||||||||||
| Operating Expenses | 885.3 | 811.7 | 744.8 | 640.8 | 607.2 | 508.7 | 414.8 | 409.2 | 324.6 | 295.0 | 243.5 | 226.3 | 227.9 | 286.9 | 262.4 | 260.5 | 251.0 | 218.4 | 247.7 | 138.2 | 95.1 | 86.7 | 77.0 | 70.1 | 55.4 | 35.4 |
| Selling, General and Administrative Expenses | 747.9 | 665.1 | 619.9 | 528.9 | 517.6 | 443.9 | 373.4 | 367.5 | 300.4 | 269.0 | 225.7 | 208.2 | 206.1 | 262.5 | 234.0 | 230.2 | 217.5 | 180.8 | 189.5 | 121.4 | 90.2 | 83.3 | 68.3 | 51.2 | 39.8 | 34.1 |
| Research and Development Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | 617.3 | 651.0 | 589.9 | 432.7 | 351.2 | 331.4 | 287.5 | 237.4 | 206.4 | 177.7 | 151.4 | 165.8 | 174.3 | (298.5) | 166.9 | (449.8) | 227.2 | 188.2 | 181.0 | 160.3 | 138.6 | 122.3 | 90.3 | 65.1 | 43.0 | 35.3 |
| PRE-TAX INCOME | ||||||||||||||||||||||||||
| Interest Income Expense | 136.7 | 59.3 | 73.9 | 86.4 | 60.9 | 63.8 | 29.8 | 27.7 | 15.1 | 11.9 | 21.0 | 33.3 | 41.2 | 34.1 | 21.7 | 14.0 | 14.8 | 193.2 | 22.6 | 8.7 | 6.6 | 27.3 | 27.3 | 67.4 | 8.3 | (2.1) |
| Total Other Income | (36.0) | (28.0) | (109.2) | 14.4 | (47.1) | (49.7) | 8.7 | (14.5) | (11.0) | 75 K | (13.1) | (36.0) | (41.6) | (35.6) | (17.8) | (10.1) | (9.8) | (11.6) | (17.1) | (9.9) | (5.9) | (37.7) | (27.8) | (39.3) | (10.3) | 0.5 |
| Pre-Tax Income | 581.3 | 623.0 | 480.7 | 447.1 | 304.1 | 281.7 | 297.0 | 222.9 | 195.4 | 177.6 | 138.3 | 129.7 | 132.7 | (334.1) | 149.1 | (461.0) | 217.4 | 176.6 | 160.4 | 152.5 | 132.6 | 114.4 | 69.5 | 25.7 | 32.7 | 35.8 |
| NET INCOME | ||||||||||||||||||||||||||
| Tax Provision | 100.9 | 130.4 | 81.9 | 81.8 | 50.0 | 54.5 | 171.4 | 66.8 | 43.4 | 47.7 | 32.9 | 27.6 | 17.1 | 23 K | 39.7 | 61.9 | 59.4 | 49.7 | 16.6 | 61.2 | 51.1 | 43.6 | 27.1 | 7.8 | 15.6 | 14.1 |
| Net Income | 474.6 | 486.2 | 391.0 | 364.3 | 252.0 | 226.4 | 123.4 | 154.8 | 149.3 | 126.7 | 102.8 | 97.3 | 109.6 | (336.7) | 114.4 | (521.8) | 154.4 | (55.8) | 142.0 | 89.8 | 80.2 | 50.1 | 35.4 | (11.2) | 17.1 | 23.4 |
| EPS | 9.27 | 9.57 | 7.77 | 7.35 | 5.17 | 4.72 | 2.6 | 3.29 | 3.21 | 2.72 | 2.15 | 2.03 | 2.16 | 5.38 | 1.75 | 7.76 | 2.31 | 0.81 | 2.04 | 1.81 | 1.76 | 1.12 | 0.86 | 0.4 | 0.86 | 2.27 |